ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The Effects of Drug Exposure and Single Nucleotide Polymorphisms on Aaptinib-Induced Severe Toxicities in Solid Tumors

Chen, Youhao; Lin, Yaobin; Guan, Shaoxing; Zhao, Zerui; Lin, Daren; Guan, Jin; Zhou, Chengzhi; Liu, Junling; Cao, Xiaolong; Lin, Zhichao; Chen, Diyao; Shang, Jianbiao; Zhang, Weijian; Chen, Huohui; Chen, Likun; Ma, Shudong; Gu, Lijia; Zhao, Jian; Huang, Min*; Wang, Xueding*; Long, Hao*佛山市第一人民医院; 广州医学院; 南方医科大学; 中山大学; 1
Drug Metabolism and Disposition2023-12-1DOI: 10.1124/dmd.123.001428
4阅读
引用收藏
分享

摘要

To investigate the value of drug exposure and host germline genetic factors in predicting apatinib (APA)-related toxicities.Method: In this prospective study, plasma APA concentrations were quantified using liquid chromatography with tandem mass spectrometry, and 57 germ line mutations were genotyped in 126 advanced solid tumor patients receiving 250 mg daily APA, a vascular endothelial growth factor receptor II inhibitor. The correlation between drug exposure, genetic factors, and the toxicity profile was analyzed.Results: Non-small cell lung cancer (NSCLC) was more prone to APA-related toxicities and plasma concentrations of APA, and its main metabolite M1-1 could be associated with high-grade adverse events (AEs) (P < 0.01; M1-1, P < 0.01) and high-grade antiangiogenetic toxicities (APA, P 5 0.034; P < 0.05), including hypertension, proteinuria, and hand-foot syndrome, in the subgroup of NSCLC. Besides, CYP2C9 rs34532201 TT carriers tended to have higher levels of APA (P < 0.001) and M1-1 (P < 0.01), whereas CYP2C9 rs1936968 GG carriers were predisposed to higher levels of M1-1 (P < 0.01).Conclusion: Plasma APA and M1-1 exposures were able to predict severe AEs in NSCLC patients. Dose optimization and drug exposure monitoring might need consideration in NSCLC patients with CYP2C9 rs34532201 TT and rs1936968 GG.

学科与关键词

关键词
CELL LUNG-CANCERENDOTHELIAL GROWTH-FACTORPHASE-III TRIALWILD-TYPE EGFRINDUCED HYPERTENSION1ST-LINE TREATMENTCLINICAL-TRIALAPATINIBBEVACIZUMABSORAFENIB
相关
加载中…
  • Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma
    Wang, Yonggang; Wang, Chang; Zhang, Yanqiao; Hao, Jiqing; Yang, Nong; Wang, Jvfeng; Peng, Min; Liu, Tianshu; Zhang, Guifang; Zhan, Xianbao; Zeng, Shan; Zhang, Yifan; Gao, Yong*; Yao, Yang*Frontiers in Oncology, 2022, 12: 876899.被引 1
  • FOXO3 mutation predicting gefitinib-induced hepatotoxicity in NSCLC patients through regulation of autophagy
    Guan, Shaoxing; Chen, Xi; Chen, Youhao; Wan, Guohui; Su, Qibiao; Liang, Heng; Yang, Yunpeng; Fang, Wenfeng; Huang, Yan; Zhao, Hongyun; Zhuang, Wei; Liu, Shu; Wang, Fei; Feng, Wei; Zhang, Xiaoxu; Huang, Min*; Wang, Xueding*; Zhang, Li*Acta Pharmaceutica Sinica B, 2022, 12(9): 3639-3649.被引 4
  • Apatinib successfully administered in malignant tumour patients with severe hypotension: a case series, literature review, and considerations for treatment
    Chen, Haiming; Liu, Xinfu; He, Minhong; Gu, Weiguang*; Lu, Yiyu*Journal of International Medical Research, 2023, 51(6): 03000605231177186.
查看全部 →

发表信息

论文状态
公开发表
期刊
Drug Metabolism and Disposition
发表日期
2023-12-01
卷期
第 51 卷, 第 12 期
页码
1583-1590
DOI
10.1124/dmd.123.001428
语言
ENGLISH
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81973398, 81730103, 81573507, 82020108031]; National Key Research and Development Program [2017YFC0909300, 2016YFC0905000]; Guangdong Provincial Key Laboratory of Construction Foundation [2017B030314030, 2020B1212060034]; Science and Technology Program of Guangzhou [201607020031]; National Engineering and Technology Research Center for New drug Druggability Evaluation [2017B090903004]; The 111 Project [B16047]; China Postdoctoral Science Foundation [2019M66324, 2020M683140, 2020M683139]; Guangdong Basic and Applied Basic Research Foundation [2022A1515012549, 2023A1515012667]

作者

  • C

    Chen, Youhao (第一作者)

    sun yat sen univ

  • L

    Lin, Yaobin

    sun yat sen univ

查看全部 21 位作者收起作者
  • G

    Guan, Shaoxing

    sun yat sen univ

  • Z

    Zhao, Zerui

    sun yat sen univ

  • L

    Lin, Daren

  • G

    Guan, Jin

  • Z

    Zhou, Chengzhi

    1 · guangzhou med univ

  • L

    Liu, Junling

    sun yat sen univ

  • C

    Cao, Xiaolong

    guangzhou panyu cent hosp

  • L

    Lin, Zhichao

  • C

    Chen, Diyao

    first hosp foshan

  • S

    Shang, Jianbiao

  • Z

    Zhang, Weijian

  • C

    Chen, Huohui

  • C

    Chen, Likun

    sun yat sen univ

  • M

    Ma, Shudong

    southern med univ

  • G

    Gu, Lijia

    sun yat sen univ

  • Z

    Zhao, Jian

    guangzhou med univ

  • H

    Huang, Min (通讯)

  • W

    Wang, Xueding (通讯)

  • L

    Long, Hao (通讯)

    sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417